Journal: Medical Hypothesis, Discovery and Innovation in Ophthalmology

Article Title: Pazopanib Selectively Inhibits Choroidal Vascular Endothelial Cell Proliferation and Promotes Apoptosis

doi:

Figure Lengend Snippet: Proliferation of CVECs in response to different concentrations of pazopanib at various time points. The proliferation rates were assessed using WST-1 assay.

Article Snippet: Treatment of CVECs with Pazopanib CVECs were treated with increasing doses of pazopanib (Santa Cruz, The USA) at concentrations of 10, 50, 100 and 250 μM.

Techniques: Incubation, Concentration Assay

Journal: Medical Hypothesis, Discovery and Innovation in Ophthalmology

Article Title: Pazopanib Selectively Inhibits Choroidal Vascular Endothelial Cell Proliferation and Promotes Apoptosis

doi:

Figure Lengend Snippet: Effect of pazopanib (10, 50, 100, and 250 µM) on choroidal vascular endothelial cells (CVECs) enriched with vascular endothelial growth factor (VEGF: 50ng/mL). Cell proliferation was determined by WST-1 assay at different time intervals. Results expressed as percentage of cell proliferation compared to control. A. 48h, B. 72h, and, C. 1 Week. Abbreviations: µM: micromole; ng/mL: nanogram per millilitre; h: hour; %: percentage; Conc.: concentration.

Article Snippet: Treatment of CVECs with Pazopanib CVECs were treated with increasing doses of pazopanib (Santa Cruz, The USA) at concentrations of 10, 50, 100 and 250 μM.

Techniques: WST-1 Assay, Control, Concentration Assay

Journal: Medical Hypothesis, Discovery and Innovation in Ophthalmology

Article Title: Pazopanib Selectively Inhibits Choroidal Vascular Endothelial Cell Proliferation and Promotes Apoptosis

doi:

Figure Lengend Snippet: The percentage of viable cells of VEGF enriched CVECs in response to pazopanib treatment at different concentrations and various time points. The cells viability rates were assessed using trypan blue exclusion assay as described in methods.

Article Snippet: Treatment of CVECs with Pazopanib CVECs were treated with increasing doses of pazopanib (Santa Cruz, The USA) at concentrations of 10, 50, 100 and 250 μM.

Techniques: Trypan Blue Exclusion Assay, Incubation, Concentration Assay

Journal: Medical Hypothesis, Discovery and Innovation in Ophthalmology

Article Title: Pazopanib Selectively Inhibits Choroidal Vascular Endothelial Cell Proliferation and Promotes Apoptosis

doi:

Figure Lengend Snippet: Effect of pazopanib (10, 50, 100, 250 µM) on choroidal vascular endothelial cells (CVECs) enriched with vascular endothelial growth factor (VEGF: 50ng/mL). Cell viability was defined by trypan blue assay using ViCell XR Cell analyzer at different time intervals. Results expressed as percentage of cell proliferation compared to control. A. 48h, B. 72h, and, C. 1 Week. Abbreviations: µM: micromole; ng/mL: nanogram per millilitre; h: hour; %: percentage; Conc.: concentration.

Article Snippet: Treatment of CVECs with Pazopanib CVECs were treated with increasing doses of pazopanib (Santa Cruz, The USA) at concentrations of 10, 50, 100 and 250 μM.

Techniques: Control, Concentration Assay

Journal: Medical Hypothesis, Discovery and Innovation in Ophthalmology

Article Title: Pazopanib Selectively Inhibits Choroidal Vascular Endothelial Cell Proliferation and Promotes Apoptosis

doi:

Figure Lengend Snippet: Reactive oxygen species (ROS) levels measured using dihydrorhodamine 123 (DHR 123) after exposure to various concentrations of pazopanib at different time intervals. A. 48h, B. 72h, and, C. 1 Week.

Article Snippet: Treatment of CVECs with Pazopanib CVECs were treated with increasing doses of pazopanib (Santa Cruz, The USA) at concentrations of 10, 50, 100 and 250 μM.

Techniques:

Journal: Medical Hypothesis, Discovery and Innovation in Ophthalmology

Article Title: Pazopanib Selectively Inhibits Choroidal Vascular Endothelial Cell Proliferation and Promotes Apoptosis

doi:

Figure Lengend Snippet: Measurement of activated caspase-3 levels in CVECs enriched with VEGF treated with different concentrations of pazopanib at 72h showed a 5-fold increase in activated caspase 3 levels compared to control. Abbreviations: µM: micromole; h: hour; VEGF: vascular endothelial growth factor; CVECs: choroidal vascular endothelial cells; Conc.: concentration.

Article Snippet: Treatment of CVECs with Pazopanib CVECs were treated with increasing doses of pazopanib (Santa Cruz, The USA) at concentrations of 10, 50, 100 and 250 μM.

Techniques: Control, Concentration Assay

Journal: Medical Hypothesis, Discovery and Innovation in Ophthalmology

Article Title: Pazopanib Selectively Inhibits Choroidal Vascular Endothelial Cell Proliferation and Promotes Apoptosis

doi:

Figure Lengend Snippet: Effect of different concentrations of pazopanib on cell morphology of VEGF enriched choroidal vascular endothelial cells at 72 hrs; Decrease in cell size and irregular membrane was observed compared to controls. Bright field images were taken at 20X magnification (A‐E: Control, 10, 50, 100 and 250 micrometer).

Article Snippet: Treatment of CVECs with Pazopanib CVECs were treated with increasing doses of pazopanib (Santa Cruz, The USA) at concentrations of 10, 50, 100 and 250 μM.

Techniques: Membrane, Control

Journal: Research

Article Title: STAT2/SLC27A3/PINK1-Mediated Mitophagy Remodeling Lipid Metabolism Contributes to Pazopanib Resistance in Clear Cell Renal Cell Carcinoma

doi: 10.34133/research.0539

Figure Lengend Snippet: SLC27A3 mediates mitophagy by regulating ROS levels, affecting LD formation and TKI resistance in ccRCC. (A) TEM analysis revealed a reduction in mitophagy in 786-O-PR cells following SLC27A3 knockdown (original magnification, ×1,200 and ×5,000, respectively). Red arrow, LD. (B) Expression levels of mitophagy-related proteins between 786-O-PR and 786-O-PR cells with SLC27A3 knocked down. (C and D) Proliferation ability of 786-O-PR cells stably transfected with PINK1-OE plasmids, or SLC27A3-sh was detected by colony formation and CCK-8 assays. (E and F) Proliferation ability of 786-O cells stably transfected with SLC27A3-OE plasmids or PINK1-sh was detected by colony formation and CCK-8 assays. (G and H) Proliferation ability of 786-O cells stably transfected with SLC27A3-OE plasmids or added with 3-MA was detected by colony formation and CCK-8 assays. (I) LD in the SLC27A3-OE treatment group, SLC27A3-OE cotreatment group with PINK1-sh, and the control group detected by BODIPY and Oil Red O staining. (J) LDs in the SLC27A3-OE treatment group, SLC27A3-OE cotreatment group with 3-MA, and the control group detected by BODIPY and Oil Red O staining. (K) The DCF fluorescence level of ROS was detected by flow cytometry. (L) MMP levels were measured by JC-1 fluorescence probe. (M) Expression level of mitophagy-related proteins in 786-O cells tested by Western blot. (N) Lipomic analysis of long-chain fatty acyl-CoA between SLC27A3 knockdown and control group in pazopanib-resistant cells.

Article Snippet: Parental 786-O cells were stably passaged at least 5 times after being exposed to pazopanib hydrochloride (MedChemExpress, USA) at an initial concentration of 2 μM.

Techniques: Knockdown, Expressing, Stable Transfection, Transfection, CCK-8 Assay, Control, Staining, Fluorescence, Flow Cytometry, Western Blot